Literature DB >> 29038268

Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake.

G Martín-Gutiérrez1,2, F Docobo-Pérez2,3,4, J Rodriguez-Beltrán5, J M Rodríguez-Martínez2,3,4, J Aznar1,2,4, A Pascual2,6,3,4, J Blázquez7,3,8.   

Abstract

The steps by which Escherichia coli strains harboring mutations related to fosfomycin (FOS) resistance arise and spread during urinary tract infections (UTIs) are far from being understood. The aim of this study was to evaluate the effects of urine, pH, and anaerobiosis on FOS activity against a set of isogenic strains carrying the most prevalent chromosomal mutations conferring FOS resistance (ΔuhpT, ΔglpT, ΔcyaA, and ΔptsI), either singly or in combination. We also studied fosfomycin-resistant E. coli clinical isolates from patients with UTI. Our results demonstrate that urinary tract physiological conditions might have a profound impact on FOS activity against strains with chromosomal FOS resistance mutations. Specifically, acidic pH values and anaerobiosis convert most of the strains categorized as resistant to fosfomycin according to the international guidelines to a susceptible status. Therefore, urinary pH values may have practical interest in the management of UTIs. Finally, our results, together with the high fitness cost associated with FOS resistance mutations, might explain the low prevalence of fosfomycin-resistant E. coli variants in UTIs.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Escherichia coli; UTI; chromosomal mutations; fosfomycin activity; fosfomycin resistance; urinary tract infection

Mesh:

Substances:

Year:  2017        PMID: 29038268      PMCID: PMC5740309          DOI: 10.1128/AAC.01899-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

1.  Prolonged treatment with large doses of fosfomycin plus vancomycin and amikacin in a case of bacteraemia due to methicillin-resistant Staphylococcus epidermidis and IMP-8 metallo-β-lactamase-producing Klebsiella oxytoca.

Authors:  Salvador Vergara-López; M Carmen Domínguez; M Carmen Conejo; Álvaro Pascual; Jesús Rodríguez-Baño
Journal:  J Antimicrob Chemother       Date:  2014-09-01       Impact factor: 5.790

2.  Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited.

Authors:  Gunnar Kahlmeter; Hanna Odén Poulsen
Journal:  Int J Antimicrob Agents       Date:  2011-11-03       Impact factor: 5.283

Review 3.  The epidemiology of urinary tract infection.

Authors:  Betsy Foxman
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

4.  A theoretical and experimental analysis of bacterial growth in the bladder.

Authors:  D M Gordon; M A Riley
Journal:  Mol Microbiol       Date:  1992-02       Impact factor: 3.501

5.  Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.

Authors:  Annika I Nilsson; Otto G Berg; Olle Aspevall; Gunnar Kahlmeter; Dan I Andersson
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

6.  Some unusual features of gouty arthritis in females.

Authors:  T F Yü
Journal:  Semin Arthritis Rheum       Date:  1977-02       Impact factor: 5.532

7.  Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant Escherichia coli.

Authors:  Guillermo Martín-Gutiérrez; Jerónimo Rodríguez-Beltrán; José Manuel Rodríguez-Martínez; Coloma Costas; Javier Aznar; Álvaro Pascual; Jesús Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

8.  Trometamol-fosfomycin (Monuril) bioavailability and food-drug interaction.

Authors:  E Bergogne-Bérézin; C Muller-Serieys; M L Joly-Guillou; N Dronne
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

Review 9.  Epidemiology of urinary tract infections: incidence, morbidity, and economic costs.

Authors:  Betsy Foxman
Journal:  Am J Med       Date:  2002-07-08       Impact factor: 4.965

Review 10.  Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance.

Authors:  Alfredo Castañeda-García; Jesús Blázquez; Alexandro Rodríguez-Rojas
Journal:  Antibiotics (Basel)       Date:  2013-04-16
View more
  7 in total

1.  Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis.

Authors:  Annabelle Pourbaix; François Guérin; Charles Burdet; Laurent Massias; Françoise Chau; Vincent Cattoir; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 2.  Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems.

Authors:  Bradley J Gardiner; Andrew J Stewardson; Iain J Abbott; Anton Y Peleg
Journal:  Aust Prescr       Date:  2019-02-01

3.  Fosfomycin resistance in community-acquired urinary pathogens from Western Cape, South Africa.

Authors:  Lesedi B Mosime; Mae Newton-Foot; Pieter Nel
Journal:  S Afr J Infect Dis       Date:  2022-01-19

4.  Fosfomycin Resistance Evolutionary Pathways of Stenotrophomonas maltophilia in Different Growing Conditions.

Authors:  Teresa Gil-Gil; José L Martínez
Journal:  Int J Mol Sci       Date:  2022-01-20       Impact factor: 5.923

5.  Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.

Authors:  Iain J Abbott; Elke van Gorp; Kelly L Wyres; Steven C Wallis; Jason A Roberts; Joseph Meletiadis; Anton Y Peleg
Journal:  J Antimicrob Chemother       Date:  2022-04-27       Impact factor: 5.758

Review 6.  The intriguing biology and chemistry of fosfomycin: the only marketed phosphonate antibiotic.

Authors:  Yingying Cao; Qingyao Peng; Shanni Li; Zixin Deng; Jiangtao Gao
Journal:  RSC Adv       Date:  2019-12-19       Impact factor: 4.036

7.  Novel Chromosomal Mutations Responsible for Fosfomycin Resistance in Escherichia coli.

Authors:  Vincent Cattoir; Annabelle Pourbaix; Mélanie Magnan; Françoise Chau; Victoire de Lastours; Brice Felden; Bruno Fantin; François Guérin
Journal:  Front Microbiol       Date:  2020-10-20       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.